Stock listing
NASDAQ:NIKI Niki BioSolutions, Inc. Stock
Follow Niki BioSolutions, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:NIKI
$1.57 USD -0.03 (-1.9%)
Close on Nov 20, 2026
- Day range
- $1.52 – $1.62 USDNov 20, 2026
- Volume
- 6,695 sharesNov 20, 2026
- Market cap
- $4.61M USDAt the close on Nov 20, 2026 · price × 2.94M shares outstanding
- 52-week range
- $1.42 – $14.40 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $556,708 USDMedian day 18,788 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NIKI · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.57 | -0.03 | -1.9% | $1.61 | $1.624 | $1.52 | 6,695 | |
| $1.60 | +0.10 | +6.7% | $1.505 | $1.69 | $1.48 | 7,532 | |
| $1.50 | -0.20 | -11.8% | $1.71 | $1.71 | $1.50 | 4,987 | |
| $1.70 | +0.05 | +3.0% | $1.615 | $1.70 | $1.56 | 9,579 | |
| $1.65 | -0.05 | -2.9% | $1.711 | $1.745 | $1.65 | 5,984 | |
| $1.70 | +0.13 | +8.3% | $1.57 | $1.90 | $1.505 | 66,677 | |
| $1.57 | -0.04 | -2.5% | $1.60 | $1.65 | $1.44 | 18,788 | |
| $1.61 | -0.14 | -8.0% | $1.69 | $1.71 | $1.61 | 33,404 | |
| $1.75 | +0.17 | +10.8% | $1.651 | $1.75 | $1.651 | 38,266 | |
| $1.58 | +0.08 | +5.3% | $1.48 | $1.66 | $1.48 | 9,673 | |
| $1.50 | -0.19 | -11.2% | $1.64 | $1.64 | $1.415 | 5,286 | |
| $1.69 | -0.07 | -4.0% | $1.75 | $1.83 | $1.68 | 69,480 | |
| $1.76 | +0.07 | +4.1% | $1.72 | $1.80 | $1.69 | 45,140 | |
| $1.69 | -0.08 | -4.5% | $1.79 | $1.79 | $1.67 | 25,505 | |
| $1.77 | -0.186 | -9.5% | $1.81 | $1.925 | $1.70 | 9,700 | |
| $1.956 | +0.036 | +1.9% | $1.873 | $1.96 | $1.81 | 5,600 | |
| $1.92 | 0.00 | 0.0% | $1.94 | $2.087 | $1.78 | 5,400 | |
| $1.92 | +0.03 | +1.6% | $1.953 | $2.141 | $1.91 | 12,800 | |
| $1.89 | +0.06 | +3.3% | $2.00 | $2.05 | $1.89 | 12,600 | |
| $1.83 | -0.03 | -1.6% | $1.94 | $1.94 | $1.81 | 5,100 | |
| $1.86 | -0.14 | -7.0% | $1.92 | $1.95 | $1.81 | 15,000 | |
| $2.00 | -0.03 | -1.5% | $1.91 | $2.10 | $1.83 | 10,500 | |
| $2.03 | -0.05 | -2.4% | $2.07 | $2.14 | $1.90 | 22,600 | |
| $2.08 | +0.05 | +2.5% | $2.11 | $2.24 | $1.91 | 9,600 | |
| $2.03 | -0.19 | -8.6% | $2.32 | $2.40 | $1.94 | 24,900 | |
| $2.22 | +0.075 | +3.5% | $2.32 | $2.66 | $2.12 | 51,900 | |
| $2.145 | -0.48 | -18.3% | $2.58 | $2.65 | $2.145 | 21,400 | |
| $2.625 | -0.395 | -13.1% | $2.99 | $3.22 | $2.625 | 24,800 | |
| $3.02 | -0.98 | -24.5% | $3.84 | $3.84 | $3.02 | 15,800 | |
| $4.00 | -0.32 | -7.4% | $4.12 | $4.38 | $4.00 | 8,100 | |
| $4.32 | -0.33 | -7.1% | $4.66 | $4.68 | $4.10 | 15,900 | |
| $4.65 | -0.31 | -6.2% | $4.62 | $4.80 | $4.60 | 4,600 | |
| $4.96 | +0.231 | +4.9% | $4.775 | $4.96 | $4.69 | 7,500 | |
| $4.729 | +0.129 | +2.8% | $4.74 | $4.79 | $4.63 | 3,700 | |
| $4.60 | -0.21 | -4.4% | $4.71 | $4.86 | $4.545 | 12,900 | |
| $4.81 | -0.09 | -1.8% | $5.04 | $5.17 | $4.65 | 7,900 | |
| $4.90 | +0.16 | +3.4% | $4.81 | $4.90 | $4.782 | 4,000 | |
| $4.74 | +0.04 | +0.9% | $4.87 | $5.00 | $4.624 | 14,600 | |
| $4.70 | -0.06 | -1.3% | $4.60 | $4.75 | $4.56 | 22,100 | |
| $4.76 | -0.21 | -4.2% | $5.08 | $5.14 | $4.66 | 58,400 | |
| $4.97 | +0.29 | +6.2% | $4.75 | $5.00 | $4.52 | 27,000 | |
| $4.68 | -0.14 | -2.9% | $4.69 | $4.915 | $4.68 | 7,100 | |
| $4.82 | -0.15 | -3.0% | $4.91 | $5.14 | $4.73 | 64,900 | |
| $4.97 | +0.25 | +5.3% | $4.74 | $5.00 | $4.68 | 18,800 | |
| $4.72 | -0.54 | -10.3% | $5.23 | $5.24 | $4.711 | 136,600 | |
| $5.26 | +0.49 | +10.3% | $4.85 | $5.29 | $4.78 | 137,400 | |
| $4.77 | -0.30 | -5.9% | $5.039 | $5.105 | $4.648 | 15,800 | |
| $5.07 | -0.77 | -13.2% | $5.82 | $5.82 | $5.05 | 44,500 | |
| $5.84 | +0.13 | +2.3% | $5.89 | $5.89 | $5.57 | 77,200 | |
| $5.71 | -0.52 | -8.3% | $6.08 | $6.20 | $5.68 | 36,600 | |
| $6.23 | +0.22 | +3.7% | $6.00 | $6.33 | $5.91 | 44,000 | |
| $6.01 | -0.27 | -4.3% | $6.23 | $6.47 | $5.91 | 31,200 | |
| $6.28 | +0.08 | +1.3% | $6.16 | $6.50 | $5.91 | 115,600 | |
| $6.20 | -0.31 | -4.8% | $7.15 | $9.68 | $6.05 | 4,135,100 | |
| $6.51 | -0.10 | -1.5% | $6.48 | $6.70 | $6.48 | 5,900 | |
| $6.61 | -0.01 | -0.2% | $7.16 | $7.29 | $6.55 | 31,200 | |
| $6.62 | -0.24 | -3.5% | $6.89 | $7.07 | $6.51 | 116,200 | |
| $6.86 | -0.04 | -0.6% | $6.692 | $7.15 | $6.55 | 94,300 | |
| $6.90 | -0.64 | -8.5% | $7.61 | $7.61 | $6.90 | 25,900 | |
| $7.54 | -0.305 | -3.9% | $7.74 | $7.84 | $7.50 | 14,800 | |
| $7.845 | -0.06 | -0.8% | $7.67 | $7.88 | $7.64 | 7,700 | |
| $7.905 | -0.105 | -1.3% | $8.14 | $8.30 | $7.905 | 22,600 | |
| $8.01 | -0.57 | -6.6% | $8.46 | $8.61 | $8.01 | 259,300 | |
| $8.58 | +0.38 | +4.6% | $8.31 | $9.01 | $7.75 | 30,500 | |
| $8.20 | +0.05 | +0.6% | $8.20 | $8.40 | $8.00 | 8,100 |
Splits
2 splits since 2023 · NASDAQ:NIKI · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:NIKI
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Niki BioSolutions Announces Presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 Conference
Latest deck · Sep 14, 2026
H.C. Wainwright Global Investment Conference, September 2026
Conference · 21 slides
Latest news
Niki BioSolutions Announces Presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 Conference
Nov 9, 2026
Closed $1.75 (+10.8%) on Nov 9, 2026
Niki BioSolutions Announces New York State Approval for Its APOE Genotyping Test Using Dried Blood Spots, Plasma, and Urine
Oct 26, 2026
Closed $1.89 (+3.3%) on Oct 26, 2026
Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research
Oct 23, 2026
Closed $1.83 (-1.6%) on Oct 23, 2026
Niki BioSolutions, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 4 in the last 12 months · 4 in all · newest Nov 9, 2026 · oldest 2026
- Decks
- 17 decks · latest Sep 14, 2026
Valuation
Price/book 0.2× against a median of 0.7×: the lowest of 9 Diagnostics & research services companies shown. Statements: Year to Dec 31, 2025 · price Nov 20, 2026
- Enterprise value
- $4.60M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.46
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Niki BioSolutions, Inc. · NASDAQ:NIKI | US$4.61M | US$4.60M | n/a | n/a | n/a | 0.2× | n/a | 0.1× | 1.46 |
| Nanologica AB · OMXSTO:NICA | US$5.29M | US$8.67M | 2.9× | 1.6× | n/a | 0.3× | 34.9% | 0.3× | n/a |
| VivoSim Labs, Inc. · NASDAQ:VIVS | US$5.29M | −US$2.76M | n/a | −20.5× | n/a | 0.7× | n/a | 0.1× | 1.91 |
| Biomerica, Inc. · NASDAQ:BMRA | US$4.97M | US$2.23M | n/a | 0.5× | n/a | 1.4× | −115.5% | 0.0× | 0.71 |
| VolitionRx Limited · AMEX:VNRX | US$4.87M | US$9.19M | n/a | 2.7× | n/a | n/a | −698.5% | n/a | 1.52 |
| Boule Diagnostics AB · OMXSTO:BOUL | US$4.84M | US$24.70M | n/a | 0.6× | n/a | 0.3× | −4.0% | 1.3× | n/a |
| BioInfra Co.,Ltd. · KRX:199730 | US$4.75M | −US$509,202 | n/a | −0.0× | n/a | 0.5× | −32.3% | 0.0× | n/a |
| Cardio Diagnostics Holdings Inc. · NASDAQ:CDIO | US$4.74M | US$4.74M | n/a | 312× | n/a | 0.8× | n/a | 0.0× | 2.07 |
| Cambridge Nutritional Sciences PLC · LSE:CNSL | US$4.51M | US$1.23M | n/a | 0.1× | n/a | 0.6× | −83.5% | 0.0× | n/a |
| Proteome Sciences plc · LSE:PRM | US$4.45M | US$23.87M | n/a | 4.9× | n/a | n/a | −81.5% | n/a | n/a |
| Immunovia AB · OMXSTO:IMMNOV | US$3.95M | US$2.31M | n/a | 12.1× | n/a | 6.1× | n/a | 0.4× | n/a |
| Median of the others | US$4.80M | US$3.52M | 2.9× | 1.1× | 0.7× | −81.5% | 0.1× | 1.72 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H.C. Wainwright Global Investment Conference, September 2026 | Conference | 21 slides | Sep 14, 2026 |
| Aptorum Group — HCW Conference September 2025 | Conference | 16 slides | Sep 10, 2025 |
| Aptorum Group — Technical Presentation (June 2022) | Technical | 18 slides | Jun 9, 2022 |
| Aptorum Group — Investor Presentation (June 2022) | Investor deck | 30 slides | Jun 9, 2022 |
| Aptorum Group — Investor Presentation (January 2022) | Investor deck | 27 slides | Jan 10, 2022 |
| Aptorum Group — Investor Presentation (January 2021) | Investor deck | 24 slides | Jan 22, 2021 |
| Aptorum Group — Investor Presentation (October 2020) | Investor deck | 28 slides | Oct 20, 2020 |
| Aptorum Group — Investor Presentation (September 2020) | Investor deck | 36 slides | Sep 1, 2020 |
| Aptorum Group — Investor Presentation (June 2020) | Investor deck | 33 slides | Jun 29, 2020 |
| Aptorum Group — Investor Presentation (February 2020) | Investor deck | 49 slides | Feb 10, 2020 |
All 17 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Aptorum Group — Investor Presentation (October 2019) | Investor deck | 43 slides | Oct 25, 2019 |
| Aptorum Group — Investor Presentation (September 2019) | Investor deck | 55 slides | Sep 9, 2019 |
| Aptorum Group — Investor Presentation (May 2019) | Investor deck | 12 slides | May 31, 2019 |
| Aptorum Group — Investor Presentation (May 2019) | Investor deck | 16 slides | May 31, 2019 |
| Aptorum Group — Investor Presentation (April 2019) | Investor deck | 13 slides | Apr 24, 2019 |
| Aptorum Group — Investor Presentation (March 2019) | Investor deck | 36 slides | Mar 4, 2019 |
| Aptorum Group — IPO Roadshow (October 2018) | IPO roadshow | 30 slides | Oct 10, 2018 |
IPO
Went public as Aptorum Group Ltd. Priced at US$15.80 a share on Dec 4, 2018.
- Price
- US$15.80 a share
- Shares offered
- 1,543,245 Class A ordinary shares
- Offering size
- US$24.4 million · Shares offered times the price, worked out by 6ix
- Listing
- APM on the Nasdaq Capital Market
- Shares delivered
- On or about Dec 14, 2018
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jul 13, 2018 |
| Filed publicly | Sep 5, 2018 |
| Amended 3 times | Newest Nov 28, 2018 |
| Declared effective by the SEC | Dec 3, 2018 |
| Shares registered with an exchange | Dec 14, 2018 |
| Final prospectus, with the price | Dec 4, 2018 |
Filings
| Filing | Filed |
|---|---|
| 8-A12B · Registration of shares for listing on an exchange | Dec 14, 2018 |
| UPLOAD · Letter from the SEC | Dec 12, 2018 |
| 424B4 · Prospectus | Dec 4, 2018 |
| EFFECT · Notice that a registration is effective | Dec 3, 2018 |
| CORRESP · Letter to the SEC | Nov 30, 2018 |
| CORRESP · Letter to the SEC | Nov 30, 2018 |
| F-1/A · Registration statement, amended | Nov 28, 2018 |
| CORRESP · Letter to the SEC | Nov 27, 2018 |
| UPLOAD · Letter from the SEC | Nov 26, 2018 |
| CORRESP · Letter to the SEC | Nov 15, 2018 |
All 19 filings
| Filing | Filed |
|---|---|
| F-1/A · Registration statement, amended | Nov 15, 2018 |
| UPLOAD · Letter from the SEC | Oct 11, 2018 |
| FWP · Free writing prospectus | Oct 10, 2018 |
| CORRESP · Letter to the SEC | Oct 5, 2018 |
| F-1/A · Registration statement, amended | Oct 5, 2018 |
| UPLOAD · Letter from the SEC | Sep 20, 2018 |
| CORRESP · Letter to the SEC | Sep 5, 2018 |
| F-1 · Registration statement | Sep 5, 2018 |
| DRS · Draft registration statement | Jul 13, 2018 |
Open IPO · From the cover of the final prospectus (424B4) filed Dec 4, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 431.4K | 1.30M | 1.54M | 911.5K | 535.2K | 383.4K | |
| Cost of revenue | 0 | 255.0K | 420.8K | 1.22M | 1.46M | 1.01M | 794.5K | 318.0K | 58.9K |
| Gross profit | 0 | -255.0K | 10.6K | 80.1K | 81.9K | -104.0K | -259.0K | 65.4K | -58.9K |
| Research and development | 352.9K | 2.20M | 5.20M | 9.22M | 10.9M | 11.6M | 6.94M | 3.10M | 2.50M |
| Selling, general and administrative | 1.64M | 1.46M | 4.37M | 7.87M | 8.03M | 7.71M | 10.8M | 6.73M | |
| Operating income | -1.82M | -3.80M | -10.6M | -17.5M | -19.2M | -19.9M | -18.2M | -10.3M | -5.69M |
| Depreciation and amortization | 0 | 255.0K | 1.13M | 1.21M | 1.19M | 1.33M | 1.30M | 682.3K | 58.9K |
| EBITDA | -1.82M | -3.54M | -9.48M | -16.3M | -18.0M | -18.6M | -16.9M | -9.65M | -5.63M |
| Interest expense | 95.7K | 146.9K | 121.1K | 93.6K | 243.6K | 3.70M | 4.46M | ||
| Income before tax | -1.38M | -4.16M | -4.34M | -11.5M | -27.1M | 4.92M | -20.1M | -15.1M | -2.56M |
| Income tax | -14.0K | ||||||||
| Net income | -1.36M | -4.27M | -2.82M | -9.80M | -25.0M | 4.92M | -20.1M | -14.8M | -2.55M |
| Earnings per share, basic | -0.19 | -0.78 | -0.62 | -2.75 | -7.15 | 2.03 | -0.64 | -0.53 | -84.56 |
| Earnings per share, diluted | -0.19 | -0.78 | -0.62 | -2.75 | -7.15 | 2.00 | -0.64 | -0.53 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.45M | 874.2K | 2.01M | 1.88M | 8.13M | 3.50M | 5.19M | 12.0M | 16.2M |
| Short-term investments | 0 | 102.5K | 236.6K | 28.4M | 1.06M | 1.01M | 1.97M | ||
| Receivables | 4.54K | 47.7K | 174.4K | 78.7K | 62.2K | 40.5K | 2.83K | 179.5K | |
| Inventory | 0 | 27.7K | 35.8K | 39.1K | 34.2K | 30.6K | 1.54M | ||
| Current assets | 3.59M | 959.6K | 2.48M | 7.07M | 12.7M | 33.7M | 8.03M | 28.7M | 20.3M |
| Property, plant and equipment | 1.66M | 2.83M | 3.73M | 4.69M | 7.09M | 4.26M | |||
| Total assets | 18.7M | 16.1M | 20.6M | 20.9M | 21.9M | 44.2M | 24.0M | 45.1M | 31.6M |
| Accounts payable | 40.1K | ||||||||
| Current liabilities | 4.59M | 4.34M | 2.10M | 12.5M | 4.38M | 3.87M | 2.67M | 12.2M | 1.33M |
| Long-term debt | 3.06M | 129.8K | 296.2K | 296.2K | 294.6K | 3.42M | |||
| Total debt | 3.44M | 3.35M | 3.28M | 129.8K | 296.2K | 296.2K | 294.6K | 3.42M | 480.0K |
| Total liabilities | 4.90M | 4.35M | 5.26M | 13.0M | 4.40M | 6.08M | 9.10M | 12.3M | 1.33M |
| Shareholders' equity | 23.1M | 21.1M | 24.8M | 15.7M | 23.6M | 41.8M | 16.4M | 33.1M | 30.2M |
| Shares outstanding | 73.5K | 54.5K | 45.2K | 35.7K | 35.0K | 31.5K | 29.0K | 27.9K | 30.1K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1.84M | -1.19M | -7.72M | -12.3M | -14.7M | -15.9M | -13.4M | -10.0M | -5.78M |
| Capital spending | 0 | 0 | -3.02K | -186.9K | -131.8K | -161.3K | -837.1K | -5.65M | -3.06M |
| Free cash flow | -1.84M | -1.19M | -7.73M | -12.5M | -14.8M | -16.1M | -14.2M | -15.7M | -8.84M |
| Cash from investing | 58.6K | 624.8K | 2.44M | 16.5M | 1.84M | -108.1K | -6.06M | 12.8M | |
| Cash from financing | 4.42M | 0 | 4.09M | 6.63M | 2.78M | 12.4M | -7.32M | 25.5M | 9.08M |
| Dividends paid | -755.5K | ||||||||
| Change in cash | 2.58M | -1.13M | -3.01M | -3.25M | 4.64M | -1.67M | -20.8M | 9.38M | 16.1M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| NT 10-Q · Late filing notice | Nov 17, 2026 | Explanation request | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 13, 2026 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Oct 13, 2026 | Other filings | SEC |
| 8-K · Current report | Oct 9, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Oct 9, 2026 | Offer document | SEC |
Show 200 filings
This page holds 200 of 261 filings. Open Filings
Cap table
Built by 6ix from Niki BioSolutions, Inc.’s releases
- Common shares
- 2,938,625
- Fully diluted
- 2,938,625
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 2,938,625 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 2,938,625 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Kira Sheinerman Other companies: Cardiff Oncology, Inc. (Director · Jun 12, 2008 – Jun 12, 2008 · Past) | Director · Since at least Jul 20, 2026 |
| Alidad Mireskandari | President & COO · Since at least Jul 22, 2026 |
| Laura A Philips | Director · Since at least Jul 20, 2026 |
Log in to ask 6ix AI your own questions about Niki BioSolutions, Inc.